Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Device Design & Manufacturing
repregen.com

See what CB Insights has to offer

Stage

Unattributed VC | Alive

Total Raised

$1.6M

Last Raised

$1.6M | 11 yrs ago

About RepRegen

RepRegen is an emerging medical device company using patent-pending repair and regeneration technology in two platforms designed to mend and regrow tissue in vivo.

RepRegen Headquarter Location

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing RepRegen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

RepRegen is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

RepRegen Patents

RepRegen has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/30/2010

12/1/2015

Glass compositions, Glass engineering and science, Glass chemistry, Personal care brands, Cosmetics

Grant

Application Date

6/30/2010

Grant Date

12/1/2015

Title

Related Topics

Glass compositions, Glass engineering and science, Glass chemistry, Personal care brands, Cosmetics

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.